RxSight lowers FY2026 sales guidance, reports Q2 prelim revenue $32-34M, Alcon collaboration

RxSight, Inc.

Preliminary Q2 2026 revenue $32-34M, including $5-7M from Alcon collaboration; sales ~$27M (24,917 LAL units, 11 LDD units).
FY2026 sales guidance lowered to $110-120M (from $120-135M); total revenue guidance $140-160M including collaboration revenue $30-40M.
Gross margin guidance raised to 73-75% (from 70-72%); operating expense guidance unchanged at $150-160M.
Strategic collaboration with Alcon to develop light-adjustable presbyopia-correcting IOLs; pipeline includes next-gen LAL, LAL+, LAL Toric.
Cash and investments ~$209M as of June 30, 2026; cites competitive trialing as headwind.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.